MedTrace Logo

Oliceridine Versus Sufentanil Analgesia for Postoperative Patients With Obstructive Sleep Apnea

NCT07753785 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 851

Last updated 2026-08-11

No results posted yet for this study

Summary

Opioids are frequently used for postoperative analgesia but may induce side effects. Opioid-induced respiratory depression is the most dangerous side effect of opioids. Patients with obstructive sleep apnea (OSA) are at higher risk for opioid-induced respiratory depression. Oliceridine is a novel biased μ-opioid receptor agonist that selectively engages the G-protein pathway while reducing β-arrestin recruitment and thus may lower the risk of respiratory depression. The goal of this observational study is to compare the effects of oliceridine versus sufentanil analgesia on the incidence of postoperative respiratory depression in patients with known or suspected OSA in the postoperative period following elective surgery.

Conditions

Interventions

DRUG

Oliceridine

Oliceridine will be administered via patient-controlled intravenous analgesia.

DRUG

Sufentanil

Sufentanil will be administered via patient-controlled intravenous analgesia.

Sponsors & Collaborators

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Dong-Xin Wang, MD, PhD · Peking University First Hospital

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2029-12-31
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07753785 on ClinicalTrials.gov